274 related articles for article (PubMed ID: 9494603)
1. Total and free PSA: a methodical and clinical evaluation of five assays.
Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
[TBL] [Abstract][Full Text] [Related]
2. The ratio of free to total prostate specific antigen: an advantageous addition in the differential diagnosis of benign hyperplasia and cancer of the prostate?
Reiter W; Stieber P; Schmeller N; Nagel D; Jansen HM; Schambeck C; Fabricius PG; Pahl H; Mattes M; Constabel H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2987-91. PubMed ID: 9329582
[TBL] [Abstract][Full Text] [Related]
3. Alpha 1-antichymotrypsin-PSA (ACT-PSA): a useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?
Reiter W; Stieber P; Schmeller N; Nagel D; Fateh-Moghadam A
Anticancer Res; 1997; 17(6D):4767-70. PubMed ID: 9494604
[TBL] [Abstract][Full Text] [Related]
4. The clinical value of the Enzymun-Test for total and free PSA--a multicentre evaluation.
Reiter W
Anticancer Res; 1999; 19(6C):5559-62. PubMed ID: 10697616
[TBL] [Abstract][Full Text] [Related]
5. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
Tarle M; Kraljić I
Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
[TBL] [Abstract][Full Text] [Related]
6. Is free prostate-specific antigen helpful in the differential diagnosis of benign hyperplasia and cancer of the prostate?
Reiter W; Stieber P; Schmeller N; Nagel D; Schambeck C; Fateh-Moghadam A
Tumour Biol; 1997; 18(2):80-7. PubMed ID: 9222305
[TBL] [Abstract][Full Text] [Related]
7. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
8. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I
Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
[TBL] [Abstract][Full Text] [Related]
9. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Stephan C; Lein M; Jung K; Schnorr D; Loening SA
Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
11. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
Paus E; Nilsson O; Børmer OP; Fosså SD; Otnes B; Skovlund E
J Urol; 1998 May; 159(5):1599-605. PubMed ID: 9554362
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
13. [Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)].
de la Taille A; Houlgatte A; Houdelette P; Berlizot P; Ramirez J; Ricordel I
Prog Urol; 1997 Apr; 7(2):240-5. PubMed ID: 9264766
[TBL] [Abstract][Full Text] [Related]
14. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan.
Egawa S; Soh S; Ohori M; Uchida T; Gohji K; Fujii A; Kuwao S; Koshiba K
Cancer; 1997 Jan; 79(1):90-8. PubMed ID: 8988731
[TBL] [Abstract][Full Text] [Related]
15. The variation of percent free prostate-specific antigen determined by two different assays.
Yang CR; Ou YC; Horng YY; Lee HS
Anticancer Res; 2003; 23(1B):707-11. PubMed ID: 12680171
[TBL] [Abstract][Full Text] [Related]
16. [The percentage of free prostate specific antigen used in detecting prostate cancer].
Yang L; Fang Z; Song J; Deng S
Zhonghua Wai Ke Za Zhi; 1999 Jan; 37(1):47-9. PubMed ID: 11829778
[TBL] [Abstract][Full Text] [Related]
17. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
18. First clinical results with Enzymun-Test for free PSA.
Gilson G; Lamy S; Humbel RL
Anticancer Res; 1997; 17(4B):2861-4. PubMed ID: 9329548
[TBL] [Abstract][Full Text] [Related]
19. Critical aspects related to the interpretation of the free-to-total PSA-ratio.
Wolff JM; Stocker G; Borchers H; Haubeck H; Greiling H; Jakse G
Anticancer Res; 1999; 19(4A):2633-6. PubMed ID: 10470208
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 3 investigational assays for the free form of prostate specific antigen.
Nixon RG; Meyer GE; Blase AB; Gold MH; Brawer MK
J Urol; 1998 Aug; 160(2):420-5. PubMed ID: 9679890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]